Compare Nasdaq Inc (NDAQ) vs Revvity Inc (RVTY) Price & Performance

Nasdaq (NDAQ) trades at $90.24, down 1.53% today, with a bullish technical signal from moving averages and a consensus analyst price target of $107.00. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.96 exceeding expectations, and maintains robust profitability with a net income margin of 23.03%. Recent news highlights strategic growth, including the acquisition of Nasdaq Fund Secondaries by NPM, expanding its platform beyond direct company shares.

The outlook for NDAQ is positive, supported by organic revenue growth and strategic acquisitions, though risks include market volatility and execution challenges. With 61.11% of analysts rating it a buy and a price target implying ~19% upside, the stock presents a growth opportunity for investors focused on financial infrastructure expansion, balanced by monitoring debt levels and competitive pressures.

RVTY trades at $106.44, down 3.37% today, with a bullish technical outlook despite near-term weakness. The company maintains stable revenue around $2.9B with consistent earnings beats, though valuation multiples appear elevated with a P/E of 51. Recent AI product launches and FDA clearances demonstrate innovation in life sciences and diagnostics. Analyst consensus remains positive with a $111.43 price target and no sell ratings among 29 covering firms.

The stock presents a growth opportunity with strong analyst support and technological innovation, but faces risks from margin pressure and China market exposure. Current levels near support at $105 offer potential entry, though the high P/E requires sustained earnings growth to justify valuation. Upcoming Q2 earnings on August 4, 2026 will be critical for near-term direction.